Navigation Links
Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQ's Minimum Bid Price Rule
Date:3/25/2009

--Company Now Has Until October 26, 2009 to Regain Compliance with $1.00 Minimum Bid Price Rule--

TUSTIN, Calif., March 25 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has received a letter from NASDAQ that provides Peregrine with an additional three months to regain compliance with the minimum bid price rule. Peregrine now has until October 26, 2009 to regain compliance with NASDAQ's $1.00 minimum bid price rule in order to remain listed on The Nasdaq Stock Market. This extension was granted as part of NASDAQ's recently announced temporary suspension of the minimum bid price and market value requirements for all NASDAQ-listed companies.

As previously announced, in December 2008 Peregrine received a letter from NASDAQ informing the company that the deadline for regaining compliance with the minimum bid price rule had been extended until July 27, 2009. This deadline is now extended until October 26, 2009, at which time Peregrine must evidence a closing bid price of $1.00 or more for a minimum of 10 prior consecutive trading days.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.c
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
11. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2014)... cancers are small cell lung cancers (SCLC), which ... However, researchers at Virginia Commonwealth University Massey Cancer ... leading to this resistance that may lead to ... mediating B-cell lymphoma 2 (Bcl-2) family proteins, which ... their function, this family of proteins can trigger ...
(Date:4/22/2014)... for Molecular Pathology (AMP) released a report today ... on recommendations for a molecular diagnostics curriculum at ... The report was prepared by the Medical Laboratory ... Training and Education Committee. "Our goal was to ... laboratory scientists appropriately in order to manage the ...
(Date:4/22/2014)... and rabbits, Johns Hopkins scientists have found a way ... preventing the development of atherosclerosis, the main cause of ... death among humans. The condition develops when fat builds ... narrowed and hardened, greatly reducing their ability to feed ... , In a series of experiments, described April 7 ...
(Date:4/22/2014)... in German . ... molecules, but their mode of action is complex: In ... and behavior, while at high concentrations they can cause ... analyze how redox signaling unfolds in single cells and ... been developed jointly by the teams of LMU Professor ...
(Date:4/22/2014)... a new RAND study concludes that U.S. policy makers ... device makers to develop products that produce more value. ... use, a new study suggests the study identifies options ... in the first place. The aim is to help ... health as possible and to ensure that costlier advances ...
Breaking Medicine News(10 mins):Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:Neuroimaging: Live from inside the cell 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3
... disease are receiving implantable cardioverter-defibrillators (ICDs) to maintain proper ... the 1980s, but little is known about how well ... 1 percent of recipients. A report in the April ... the largest pediatric experience to date. It finds the ...
... In a major step toward a practical energy ... development of a new generation of sub-microscopic nanomotors that ... motors. Their study is scheduled for the May 27 ... the new study, Joseph Wang and colleagues point out ...
... Campaign Encourages Consumers to Get Active and Give Back By Logging Miles ... ... A healthy lifestyle is always,important and to encourage consumers to get active, ... Breast,Cancer Organization with a donation of up to $200,000. Running from May ...
... Management to Host Conference Call Today at 11:30 a.m. ET ... a provider of liquid nutritional, functional foods, beverages and,nutritional supplements, ... 2008., Financial and operational highlights for First Quarter ... year period to $1.6 million -- Gross profit was ...
... Fla., May 1 Blue Cross and ... David Pizzo has been appointed Market,President - ... http://www.newscom.com/cgi-bin/prnh/20080501/CLTH034 ), (Logo: http://www.newscom.com/cgi-bin/prnh/20000427/BLUELOGOA ... ), Pizzo has served in a ...
... Mich., May 1 Perrigo Company,(Nasdaq: PRGO ... Directors declared a,quarterly dividend of $0.05 per share, ... on May 25, 2008., Perrigo Company is ... distributes over-the-counter (OTC) and prescription,pharmaceuticals, nutritional products, active ...
Cached Medicine News:Health News:Largest study to date finds benefits of ICDs in children 2Health News:Bumble Bee Foods Launches BeeWell Miles; An Interactive Health and Wellness Program Benefitting the Y-Me National Breast Cancer Foundation 2Health News:Bumble Bee Foods Launches BeeWell Miles; An Interactive Health and Wellness Program Benefitting the Y-Me National Breast Cancer Foundation 3Health News:XELR8 Holdings Announces Record First Quarter Revenue 2Health News:XELR8 Holdings Announces Record First Quarter Revenue 3Health News:XELR8 Holdings Announces Record First Quarter Revenue 4Health News:XELR8 Holdings Announces Record First Quarter Revenue 5Health News:XELR8 Holdings Announces Record First Quarter Revenue 6Health News:XELR8 Holdings Announces Record First Quarter Revenue 7Health News:XELR8 Holdings Announces Record First Quarter Revenue 8Health News:David Pizzo Appointed Blue Cross and Blue Shield of Florida Market President - West Florida 2
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: